| Document |
Document Title |
|
WO/2022/034587A1 |
Compounds represented by Formula (I): wherein W is a nitrogen-containing moiety attached to said X via said nitrogen atom, and all other variables are as defined in the specification, processes of preparing same and uses thereof for trea...
|
|
WO/2022/036176A1 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula I (Formula I) The variables, e.g. R1-R4, and Z are defined herein. Y is Y is (II). Certain compounds of Formula I are highly potent against resis...
|
|
WO/2022/036188A1 |
The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be u...
|
|
WO/2022/033991A1 |
The invention relates to novel compounds of formula (I), where Ar represents phenyl or a 5- or 6-membered heteroaromatic ring and A, V, R1 and R2 are defined as aforementioned, and to the use of said compounds for controlling animal pest...
|
|
WO/2022/031678A1 |
The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use ...
|
|
WO/2022/031994A1 |
Provided herewith are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre- diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and car...
|
|
WO/2022/027439A1 |
Provided are β-lactam compounds of formula (I), their preparation and use as antibiotic agents for the treatment of bacterial infections: Wherein X, W, R 1, R 2 and R 3 are defined herein.
|
|
WO/2022/031939A1 |
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of autoimmune disorders or cancer.
|
|
WO/2022/029706A1 |
The present invention relates to stable synergistic triple combination fungicidal composition comprising of a) strobilurin fungicide, b) systemic fungicide and c) polymeric dithiocarbamate fungicide complex with zinc salt. The present in...
|
|
WO/2022/031735A1 |
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods o...
|
|
WO/2022/029041A1 |
Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, n...
|
|
WO/2022/028556A1 |
Provided are a compound of formula (I) or a tautomer, a mesomer, a raceme, an enantiomer, a diastereoisomer, or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of drugs for diseases mediated by CDK9.
|
|
WO/2022/028507A1 |
A heterocyclic compound as represented by formula I, a preparation method therefor, a pharmaceutical composition comprising same and use thereof. The heterocyclic compound can be used as a complement factor B inhibitor, and is used for p...
|
|
WO/2022/022600A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2022/023315A1 |
The present invention relates to compounds for their use in the reactivation of butyrylcholinesterase. Such compounds are useful in the treatment or prevention of the intoxication with at least one organophosphorus nerve agent. The inven...
|
|
WO/2022/027058A1 |
The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degraders.
|
|
WO/2022/020967A1 |
Use of Wnt/Beta-catenin pathway inhibitors to block replication of SARS-CoV-2 and other pathogenic viruses.
|
|
WO/2022/023772A1 |
The present invention relates to compounds of formula (I) shown below: wherein R1, R2, R3, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2022/026892A1 |
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention ar...
|
|
WO/2022/023447A2 |
The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also r...
|
|
WO/2022/023353A1 |
The present application relates to substituted coumarin derivatives and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
|
|
WO/2022/019921A1 |
Provided are new nickel./zirconium-mediated coupling reactions useful in the synthesis of ketone-containing compounds, e.g., halichondrin natural products and related molecules. A feature of the present disclosure is the use of a nickel(...
|
|
WO/2022/017836A1 |
The present invention relates to fungicidal compositions comprising, as active components, (R)- 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-t
riazol-1-yl)propan-2-ol (I) and N-(2- fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4...
|
|
WO/2022/020716A1 |
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2022/020342A1 |
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
|
|
WO/2022/017371A1 |
A heterocyclic compound represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, and a use thereof as a dual inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ) and phosphatidylinositol ...
|
|
WO/2022/018182A1 |
The invention relates to a light emitting organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has - one first chemical moiety with a structure of formula I, and ...
|
|
WO/2022/015975A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013153A1 |
The present invention relates to a hydrochloride salt of 4-[(3-carbamoylphenyl)[1-(1,3-thiazol-5-ylmethyl)piperidin-4
-ylidene]methyl]-N,N-dimethylbenzamide (PN6047) and crystalline forms thereof, more specifically Form HC12 and Form HC1...
|
|
WO/2022/015979A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/011626A1 |
Disclosed are novel monobactam compounds of formula (I), their preparation and use as antibiotic agents for the treatment of bacterial infections.
|
|
WO/2022/015957A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013684A1 |
The invention relates to compounds of Formula (I) wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeu...
|
|
WO/2022/014721A1 |
The present invention addresses the problem of providing a photoelectric conversion element that has a photoelectric conversion film having superior vapor deposition suitability and exhibits excellent external quantum efficiency with res...
|
|
WO/2022/007168A1 |
The present application relates to a benzo five-membered nitrogen heterocyclic compound and an application thereof. The benzo five-membered nitrogen heterocyclic compound has the structure represented by formula I. The compound can be us...
|
|
WO/2022/007903A1 |
A compound as shown in general formula B-L-K (I) or stereoisomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or co-crystals thereof, and intermediates thereof and uses thereof for AR-related...
|
|
WO/2022/008383A1 |
The present invention discloses compounds according to Formula (I) wherein R1, R2, R3, L1, L2, and L3 are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their produ...
|
|
WO/2022/005976A2 |
Here we report the discovery of 2-(4-(3-(trifluoromethoxy)phenoxy)picolinamido) benzo[d]oxazole-5-carboxylate as an antibacterial with potent and selective activity against C. difficile. Its MIC50 andMIC90 values,documented across 101 st...
|
|
WO/2022/003426A1 |
Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
|
|
WO/2022/002011A1 |
The present invention relates to a salt of a 2-(substituted pyrimidinyl)thiazolecarboxamide compound, and a composition and use thereof, and also relates to a crystal form of the salt. Specifically, the present invention relates to a pha...
|
|
WO/2020/102100A9 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2022/002018A1 |
Disclosed in the present invention are a compound as represented by formula (I), and an isomer or a pharmaceutically acceptable salt thereof. The compound can be used for inhibiting a KRASG12C mutant protein and treating related cancers.
|
|
WO/2022/006550A1 |
The present disclosure features compounds of formula (l-a) and of formula (II) and pharmaceutical compositions thereof. The present disclosure further discloses the compounds of formula (I- a) and (II) and their compositions for use in m...
|
|
WO/2022/002193A1 |
The present invention relates to the technical field of chemical pesticides, and provides a preparation method for and an application of pyrazole acylhydrazone containing a trifluoromethyl thiadiazole unit. The pyrazole acylhydrazone con...
|
|
WO/2022/001998A1 |
Disclosed by the present disclosure is a diarylamine derivative used as a fungicide, the structural general formula of the diarylamine derivative being shown as follows. The compound disclosed has good bactericidal activity, is very effe...
|
|
WO/2021/261562A1 |
There is still a great amount of damage by pests and in production of agricultural crops, horticultural crops, and the like. The development of a novel agricultural/horticultural insecticide is desired due to factors such as the emergenc...
|
|
WO/2021/263079A1 |
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 ("TREX1").
|
|
WO/2021/261851A1 |
The present invention provides an organic electric element and an electronic device comprising the organic electric element, the organic electric element comprising an anode, a cathode, and an organic layer and a capping layer formed bet...
|
|
WO/2021/259163A1 |
Provided is a 2-N-substituted fused pyrazole-type compound, specifically a one-pot synthesis method for the preparation of a 2-N-substituted indazole-type compound. After azidizing a halogen in a substrate, no post-processing is necessar...
|
|
WO/2021/261857A1 |
The present specification relates to a heterocyclic compound and an organic light-emitting device comprising same.
|
